Trial Profile
Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient: a Prospective, Cross-sectional and Open-label 8 Week Switching Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2016
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms K-HEMS
- Sponsors Boryung Pharmaceutical
- 07 Jul 2016 Status changed from recruiting to completed.
- 25 Mar 2015 New trial record